PapersPMID:34203925
Effects of Ingesting Fucoidan Derived from Cladosiphon okamuranus Tokida on Human NK Cells: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Pilot Study.
- findings
- 3
- compound
- 1
- endpoints
- 3
- Study, every finding
- RCT · 39 participants
- Dose studied, every finding
- two bottles a day, 3 g/day of fucoidan, oral beverage
- Population, every finding
- Healthy Japanese men and women aged 20 to 65 years, 39 completers; safety blood tests over the study period, no timepoint stated in the sentence
No finding here moved its endpoint.
What did not
How to read these marks →“There were no significant differences in white blood cell count, hemoglobin, platelet count, or hematocrit between the placebo and fucoidan groups during the study period (Table 3).”
- Interests
- Industry funded
- Interests
- Industry funded
- Interests
- Industry funded
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Healthy men and women aged 20 to 65 years; fucoidan from Okinawa mozuku (Cladosiphon okamuranus, mean molecular weight 73.4 kDa) as a beverage versus placebo beverage
- Participants
- 40
- Comparator
- placebo
- Duration
- 84 days
- Endpoints measured
- 17